BRCA1 Gene Mutation Clinical Trial
Official title:
BRCAShare: Video Intervention for Relatives of BRCA Mutation-Positive Patients
This trial studies how well a video-based intervention works in helping participants encourage their families to get tested for BRCA gene mutations. Testing in families with BRCA gene mutations can allow for risk management and reduction with the overall goal of reducing cancer burden. Video-based intervention sent via text messages may help participants easily share information about BRCA gene mutations with family members.
PRIMARY OBJECTIVES: I. To understand whether the use of a video-based message to encourage cascade testing, delivered via short message service (SMS) (text message) or shared on social media, is superior to a written message as a method of information-sharing among families that have BRCA gene mutations. OUTLINE: Participants are randomized to 1 of 2 arms. ARM A: Participants receive a 2-minute information-graphic video via text message consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives that they can share with family via text message, email, or social media. ARM B: Participants receive family letter via U.S. postal service mail consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01907438 -
Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Withdrawn |
NCT02309632 -
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
|
N/A | |
Active, not recruiting |
NCT01009788 -
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
|
Phase 2 | |
Completed |
NCT01251874 -
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT02197000 -
A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers
|
N/A | |
Recruiting |
NCT03428802 -
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
|
Phase 2 | |
Completed |
NCT03377556 -
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04294927 -
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
|
N/A | |
Active, not recruiting |
NCT03943173 -
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
|
Early Phase 1 | |
Active, not recruiting |
NCT02953457 -
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
|
Phase 2 | |
Completed |
NCT01975363 -
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
|
N/A | |
Completed |
NCT01948609 -
Prospective Research of Outcomes After Salpingo-oophorectomy
|
||
Active, not recruiting |
NCT03552471 -
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
Phase 1 | |
Recruiting |
NCT02225015 -
Cancer Prevention in Women With a BRCA Mutation
|
Phase 1 | |
Active, not recruiting |
NCT02321228 -
Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers
|
N/A | |
Recruiting |
NCT04030559 -
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
|
Phase 2 | |
Terminated |
NCT01905592 -
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
|
Phase 3 | |
Recruiting |
NCT02474264 -
The Link Between BRCA Mutation and Endothelial Function
|
N/A | |
Active, not recruiting |
NCT02286687 -
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
|
Phase 2 |